Crh Medsense Simethicone 125mg Antigas

Crh Medsense Simethicone 125mg Antigas Manufacturers

• Crh Medical Corporation
  

  ×

  Crh Medsense Simethicone 125mg Antigas | Camber Pharmaceuticals, Inc.

  

  ---

  2.1 Adult Patients
  

  The recommended oral dose of lamivudine tablets in HIV-1-infected adults is 300 mg daily, administered as either 150 mg twice daily or 300 mg once daily, in combination with other antiretroviral agents. If lamivudine is administered to a patient infected with HIV-1 and HBV, the dosage indicated for HIV-l therapy should be used as part of an appropriate combination regimen [see Warnings and Precautions (5.2)].
  • Lamivudine tablets may be taken with or without food.

  　

  2.2 Pediatric Patients

  Lamivudine is also available as a scored tablet for HIV-l-infected pediatric patients who weigh at least 14 kg and for whom a solid dosage form is appropriate. Before prescribing lamivudine tablets, children should be assessed for the ability to swallow tablets. If a child is unable to reliably swallow lamivudine tablets, the oral solution formulation should be prescribed. The recommended oral dosage of lamivudine tablets for HIV-1-infected pediatric patients is presented in Table 1.

  
  

  Table 1. Dosing Recommendations for Lamivudine Scored (150-mg) Tablets in Pediatric Patients

  
  Weight (kg)
  Twice-daily Dosing Regimen Using Scored 150-mg Tablet
  AM Dose
  PM Dose
  Total Daily Dose
  14 to <20
  ½ tablet (75 mg)
  ½ tablet (75 mg)
  150 mg
  ≥20 to <25
  ½ tablet (75 mg)
  1 tablet (150 mg)
  225 mg
  ≥25
  1 tablet (150 mg)
  1 tablet (150 mg)
  300 mg
  

  Additional pediatric use information for patients aged 3 months and above is approved for ViiV Healthcare Company's EPIVIR® (lamivudine) tablets and oral solution.  However, due to ViiV Healthcare Company's marketing exclusivity rights, this drug product is not labeled with that pediatric information.
  

  
  2.3 Patients With Renal Impairment
  

  Dosing  of  lamivudine  is  adjusted  in  accordance  with  renal  function.  Dosage adjustments are listed in Table 2 [see Clinical Pharmacology (12.3)].
  
  Table 2. Adjustment of Dosage of Lamivudine in Adults and Adolescents (Greater than or Equal to 25 kg) in Accordance With Creatinine Clearance

  
  Creatinine Clearance (mL/min)
  Recommended Dosage of Lamivudine
  ≥50
  150 mg twice daily or 300 mg once daily
  30-49
  150 mg once daily
  15-29
  150 mg first dose, then 100 mg once daily
  5-14
  150 mg first dose, then 50 mg once daily
  <5
  50 mg first dose, then 25 mg once daily
  
  

  No additional dosing of lamivudine is required after routine (4-hour) hemodialysis or peritoneal dialysis.
  
  Although there are insufficient data to recommend a specific dose adjustment of lamivudine in pediatric patients with renal impairment, a reduction in the dose and/or an increase in the dosing interval should be considered.

  Close
  No Recall

  More Info